Integra Lifesciences Holdings Stock Cash And Equivalents

IART Stock

USD 22.49 0.22 0.97%

Integra LifeSciences Holdings fundamentals help investors to digest information that contributes to Integra LifeSciences' financial success or failures. It also enables traders to predict the movement of Integra Stock. The fundamental analysis module provides a way to measure Integra LifeSciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Integra LifeSciences stock.

Other Current Liab Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Integra LifeSciences Holdings Company Cash And Equivalents Analysis

Integra LifeSciences' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Cash

Bank Deposits

+

Liquidities

More About Cash And Equivalents | All Equity Analysis

Current Integra LifeSciences Cash And Equivalents

451.52 M

Most of Integra LifeSciences' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Integra LifeSciences Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Integra Cash And Equivalents Driver Correlations

Understanding the fundamental principles of building solid financial models for Integra LifeSciences is extremely important. It helps to project a fair market value of Integra Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Integra LifeSciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Integra LifeSciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Integra LifeSciences' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Intangible Assets	Short Term Investments	Short Term Debt	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Good Will	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Long Term Investments	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.97	0.45	0.85	0.85	0.96	0.99	0.96	0.98	0.73	0.01	0.86	0.84	-0.1	0.95	0.62	0.99	-0.64	0.89	0.88	0.18	0.34	0.85	0.73	0.16	0.6
Total Stockholder Equity	0.97		0.45	0.86	0.82	0.93	0.92	0.96	0.92	0.71	0.04	0.87	0.78	-0.15	0.93	0.5	0.95	-0.51	0.8	0.91	0.16	0.28	0.88	0.72	0.28	0.55
Net Debt	0.45	0.45		0.1	0.54	0.51	0.43	0.43	0.5	0.0	0.03	0.65	0.8	0.19	0.37	0.35	0.48	-0.73	0.65	0.39	0.1	-0.44	0.43	-0.12	0.69	-0.29
Retained Earnings	0.85	0.86	0.1		0.69	0.77	0.82	0.87	0.75	0.89	-0.09	0.61	0.56	-0.42	0.81	0.53	0.81	-0.21	0.61	0.74	0.04	0.39	0.73	0.9	0.06	0.76
Accounts Payable	0.85	0.82	0.54	0.69		0.92	0.84	0.78	0.85	0.47	-0.15	0.76	0.79	-0.06	0.86	0.59	0.86	-0.64	0.79	0.71	0.04	0.11	0.73	0.44	0.1	0.43
Net Receivables	0.96	0.93	0.51	0.77	0.92		0.96	0.9	0.96	0.59	0.0	0.86	0.85	-0.07	0.96	0.62	0.97	-0.69	0.87	0.82	0.17	0.3	0.81	0.56	0.08	0.52
Total Liab	0.99	0.92	0.43	0.82	0.84	0.96		0.93	0.98	0.72	-0.01	0.83	0.85	-0.06	0.93	0.68	0.99	-0.7	0.91	0.83	0.18	0.37	0.8	0.7	0.07	0.61
Total Current Assets	0.96	0.96	0.43	0.87	0.78	0.9	0.93		0.9	0.73	0.0	0.82	0.81	-0.22	0.9	0.55	0.93	-0.5	0.83	0.85	0.04	0.27	0.83	0.76	0.29	0.56
Intangible Assets	0.98	0.92	0.5	0.75	0.85	0.96	0.98	0.9		0.65	0.03	0.87	0.87	0.03	0.92	0.64	0.99	-0.77	0.92	0.85	0.27	0.33	0.81	0.63	0.11	0.54
Short Term Investments	0.73	0.71	0.0	0.89	0.47	0.59	0.72	0.73	0.65		-0.1	0.49	0.44	-0.27	0.61	0.43	0.71	-0.15	0.52	0.69	0.05	0.4	0.66	0.89	0.05	0.76
Short Term Debt	0.01	0.04	0.03	-0.09	-0.15	0.0	-0.01	0.0	0.03	-0.1		0.29	0.02	0.33	0.06	0.18	0.02	-0.05	-0.01	-0.01	0.5	0.59	-0.1	-0.05	0.05	-0.08
Common Stock	0.86	0.87	0.65	0.61	0.76	0.86	0.83	0.82	0.87	0.49	0.29		0.89	0.14	0.82	0.62	0.87	-0.68	0.88	0.86	0.25	0.24	0.85	0.45	0.37	0.18
Long Term Debt	0.84	0.78	0.8	0.56	0.79	0.85	0.85	0.81	0.87	0.44	0.02	0.89		0.04	0.76	0.71	0.86	-0.84	0.97	0.74	0.16	0.01	0.73	0.38	0.4	0.14
Treasury Stock	-0.1	-0.15	0.19	-0.42	-0.06	-0.07	-0.06	-0.22	0.03	-0.27	0.33	0.14	0.04		-0.19	-0.21	-0.02	-0.37	0.12	-0.1	-0.05	0.07	0.05	-0.33	0.0	-0.23
Property Plant Equipment	0.95	0.93	0.37	0.81	0.86	0.96	0.93	0.9	0.92	0.61	0.06	0.82	0.76	-0.19		0.6	0.94	-0.56	0.78	0.83	0.26	0.4	0.76	0.62	0.02	0.58
Current Deferred Revenue	0.62	0.5	0.35	0.53	0.59	0.62	0.68	0.55	0.64	0.43	0.18	0.62	0.71	-0.21	0.6		0.62	-0.59	0.72	0.48	0.44	0.37	0.35	0.42	-0.08	0.22
Good Will	0.99	0.95	0.48	0.81	0.86	0.97	0.99	0.93	0.99	0.71	0.02	0.87	0.86	-0.02	0.94	0.62		-0.7	0.9	0.87	0.21	0.34	0.85	0.68	0.14	0.58
Net Tangible Assets	-0.64	-0.51	-0.73	-0.21	-0.64	-0.69	-0.7	-0.5	-0.77	-0.15	-0.05	-0.68	-0.84	-0.37	-0.56	-0.59	-0.7		-0.85	-0.47	-0.31	-0.04	-0.46	-0.1	-0.13	-0.08
Long Term Debt Total	0.89	0.8	0.65	0.61	0.79	0.87	0.91	0.83	0.92	0.52	-0.01	0.88	0.97	0.12	0.78	0.72	0.9	-0.85		0.77	0.14	0.15	0.78	0.5	0.25	0.27
Capital Surpluse	0.88	0.91	0.39	0.74	0.71	0.82	0.83	0.85	0.85	0.69	-0.01	0.86	0.74	-0.1	0.83	0.48	0.87	-0.47	0.77		0.23	0.22	0.93	0.65	0.27	0.37
Deferred Long Term Liab	0.18	0.16	0.1	0.04	0.04	0.17	0.18	0.04	0.27	0.05	0.5	0.25	0.16	-0.05	0.26	0.44	0.21	-0.31	0.14	0.23		0.4	-0.06	0.02	-0.13	0.03
Short Long Term Debt	0.34	0.28	-0.44	0.39	0.11	0.3	0.37	0.27	0.33	0.4	0.59	0.24	0.01	0.07	0.4	0.37	0.34	-0.04	0.15	0.22	0.4		0.12	0.48	-0.56	0.6
Long Term Investments	0.85	0.88	0.43	0.73	0.73	0.81	0.8	0.83	0.81	0.66	-0.1	0.85	0.73	0.05	0.76	0.35	0.85	-0.46	0.78	0.93	-0.06	0.12		0.61	0.32	0.34
Net Invested Capital	0.73	0.72	-0.12	0.9	0.44	0.56	0.7	0.76	0.63	0.89	-0.05	0.45	0.38	-0.33	0.62	0.42	0.68	-0.1	0.5	0.65	0.02	0.48	0.61		0.02	0.77
Net Working Capital	0.16	0.28	0.69	0.06	0.1	0.08	0.07	0.29	0.11	0.05	0.05	0.37	0.4	0.0	0.02	-0.08	0.14	-0.13	0.25	0.27	-0.13	-0.56	0.32	0.02		-0.35
Capital Stock	0.6	0.55	-0.29	0.76	0.43	0.52	0.61	0.56	0.54	0.76	-0.08	0.18	0.14	-0.23	0.58	0.22	0.58	-0.08	0.27	0.37	0.03	0.6	0.34	0.77	-0.35

Click cells to compare fundamentals

Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).

Competition

Predict Integra LifeSciences

Integra Cash And Cash Equivalents Changes

Cash And Cash Equivalents Changes

(50.32 Million)

At this time, Integra LifeSciences' Cash And Cash Equivalents Changes is comparatively stable compared to the past year.

In accordance with the recently published financial statements, Integra LifeSciences Holdings has 451.52 M in Cash And Equivalents. This is 45.0% lower than that of the Health Care Equipment & Supplies sector and 19.08% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 83.29% higher than that of the company.

Integra Cash And Equivalents Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Integra LifeSciences' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Integra LifeSciences could also be used in its relative valuation, which is a method of valuing Integra LifeSciences by comparing valuation metrics of similar companies.

Integra LifeSciences is currently under evaluation in cash and equivalents category among its peers.

Integra LifeSciences ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Integra LifeSciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Integra LifeSciences' managers, analysts, and investors.

Environmental

Governance

Social

Integra Fundamentals

	Return On Equity	-0.0044
	Return On Asset	0.0291
	Profit Margin	(0) %
	Operating Margin	0.15 %
	Current Valuation	3.45 B
	Shares Outstanding	77.22 M
	Shares Owned By Insiders	14.24 %
	Shares Owned By Institutions	91.50 %
	Number Of Shares Shorted	3.5 M
	Price To Earning	26.94 X
	Price To Book	1.12 X
	Price To Sales	1.09 X
	Revenue	1.61 B
	Gross Profit	959.12 M
	EBITDA	193.29 M
	Net Income	(6.94 M)
	Cash And Equivalents	451.52 M
	Cash Per Share	5.41 X
	Total Debt	215.38 M
	Debt To Equity	1.03 %
	Current Ratio	3.85 X
	Book Value Per Share	20.03 X
	Cash Flow From Operations	129.38 M
	Short Ratio	6.04 X
	Earnings Per Share	(0.09) X
	Price To Earnings To Growth	1.13 X
	Target Price	26.25
	Number Of Employees	4.4 K
	Beta	1.23
	Market Capitalization	1.75 B
	Total Asset	4.04 B
	Retained Earnings	939.91 M
	Working Capital	159.56 M
	Current Asset	438.5 M
	Current Liabilities	139.13 M
	Net Asset	4.04 B

About Integra LifeSciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Integra LifeSciences Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Integra LifeSciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Integra LifeSciences Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Integra Stock Analysis

When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC